Press Releases Ypsomed Australia

Approximately 125,000 people who are living with Type 1 Diabetes in Australia could now save thousands per year under an expansion of the National Diabetes Service Scheme (NDSS) announced today.

Under changes to the NDSS, people with Type 1 Diabetes who meet the current NDSS criteria for CGM funding will now have access to reimbursed Dexcom G6 products for Continuous Glucose Monitoring (CGM) from 1 March 2022.

Previously the Dexcom G6 subsidy was only available to users of one brand of insulin pump system.

The change will improve access to this life-changing technology and drive better health outcomes for people living with Type 1 Diabetes.

Ypsomed, a leading developer and manufacturer of medical devices including insulin pumps, applauded Minister Hunt for updating the NDSS to enable insulin pump users to access subsidised Dexcom G6 Sensors.

Ypsomed Australia General Manager, James Mayjor, said this is a big win for Australians using the mylife YpsoPump insulin pump system. People living with T1 Diabetes who wish to have an integrated insulin pump with Dexcom G6 now have a choice.

“Diabetes is one of the fastest growing chronic conditions in Australia and one of the biggest challenges confronting Australia’s health system,”

Mr Mayjor said.

“Insulin pumps make life easier for people living with T1 Diabetes, and they can further improve therapy management and clinical outcomes when combined with Continuous Glucose Monitoring, but the costs add up quickly when you’re spending thousands of dollars a year for CGM.”

“I’d like to commend the Minister for Health, Greg Hunt, for expanding the NDSS to include all insulin pump users – providing equal access for the Dexcom G6 products for patients using insulin pumps. There is more work to do however, and we will continue our advocacy efforts to further expand access to Diabetes technology.”


About Ypsomed Australia

Ypsomed Australia is the Australian affiliate of Ypsomed AG, a Swiss-based company with a deep heritage in the development and manufacture of infusion and injection systems for self-medication, including insulin therapy. With over 30 years’ experience in bringing insulin-delivery devices to market, Ypsomed understands the challenges people on insulin therapy face in their everyday life, and is committed to making a difference through the design and delivery of high quality innovative & intuitive products and services.

Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries.

Go Back